201 related articles for article (PubMed ID: 29308680)
1. Prophylactic mastectomy for BRCA mutation carriers after ovarian cancer treatment: is it beneficial?
Kotsopoulos J; Narod SA
Expert Rev Anticancer Ther; 2018 Mar; 18(3):199-200. PubMed ID: 29308680
[No Abstract] [Full Text] [Related]
2. Management updates for women with a BRCA1 or BRCA2 mutation.
Nusbaum R; Isaacs C
Mol Diagn Ther; 2007; 11(3):133-44. PubMed ID: 17570734
[TBL] [Abstract][Full Text] [Related]
3. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
4. [Methods of surgical prevention of breast cancer and of ovarian cancer in BRCA mutation carriers].
Bit-Sava EM; Belogurova MB; Imianitov EN; Balandov SG; Korniushin OV; Borisov MK
Vopr Onkol; 2013; 59(2):5-11. PubMed ID: 23814843
[No Abstract] [Full Text] [Related]
5. Bilateral risk-reducing mastectomy in BRCA mutation carriers: A difficult decision-making.
Franceschini G; Masetti R
Breast J; 2019 May; 25(3):564-565. PubMed ID: 30964221
[No Abstract] [Full Text] [Related]
6. Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?
McGee J; Giannakeas V; Karlan B; Lubinski J; Gronwald J; Rosen B; McLaughlin J; Risch H; Sun P; Foulkes WD; Neuhausen SL; Kotsopoulos J; Narod SA;
Gynecol Oncol; 2017 May; 145(2):346-351. PubMed ID: 28314588
[TBL] [Abstract][Full Text] [Related]
7. The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy.
Giannakeas V; Narod SA
Breast Cancer Res Treat; 2018 Jan; 167(1):263-267. PubMed ID: 28914396
[TBL] [Abstract][Full Text] [Related]
8. Satisfaction and Impact on Quality of Life of Clinical and Instrumental Surveillance and Prophylactic Surgery in BRCA-mutation Carriers.
D'Alonzo M; Piva E; Pecchio S; Liberale V; Modaffari P; Ponzone R; Biglia N
Clin Breast Cancer; 2018 Dec; 18(6):e1361-e1366. PubMed ID: 30122348
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic mastectomy versus surveillance for the prevention of breast cancer in women's BRCA carriers.
Honold F; Camus M
Medwave; 2018 Jul; 18(4):e7161. PubMed ID: 30052622
[TBL] [Abstract][Full Text] [Related]
10. Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers.
Heemskerk-Gerritsen BAM; Jager A; Koppert LB; Obdeijn AI; Collée M; Meijers-Heijboer HEJ; Jenner DJ; Oldenburg HSA; van Engelen K; de Vries J; van Asperen CJ; Devilee P; Blok MJ; Kets CM; Ausems MGEM; Seynaeve C; Rookus MA; Hooning MJ
Breast Cancer Res Treat; 2019 Oct; 177(3):723-733. PubMed ID: 31302855
[TBL] [Abstract][Full Text] [Related]
11. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
[TBL] [Abstract][Full Text] [Related]
12. An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers.
Madorsky-Feldman D; Sklair-Levy M; Perri T; Laitman Y; Paluch-Shimon S; Schmutzler R; Rhiem K; Lester J; Karlan BY; Singer CF; Van Maerken T; Claes K; Brunet J; Izquierdo A; Teulé A; Lee JW; Kim SW; Arun B; Jakubowska A; Lubinski J; Tucker K; Poplawski NK; Varesco L; Bonelli LA; Buys SS; Mitchell G; Tischkowitz M; Gerdes AM; Seynaeve C; Robson M; Kwong A; Tung N; Tessa N; Domchek SM; Godwin AK; Rantala J; Arver B; Friedman E
Breast Cancer Res Treat; 2016 Jun; 157(2):319-327. PubMed ID: 27117159
[TBL] [Abstract][Full Text] [Related]
13. How to manage BRCA mutation carriers?
Sabiani L; Barrou J; Mathis J; Eisinger F; Bannier M; Lambaudie E; Houvenaeghel G
Horm Mol Biol Clin Investig; 2020 May; 41(3):. PubMed ID: 32459193
[TBL] [Abstract][Full Text] [Related]
14. [Problems raised by the gynaecologic management of women with BRCA 1 & 2 mutations].
Cabaret AS; Levêque J; Dugast C; Blanchot J; Grall JY
Gynecol Obstet Fertil; 2003 Apr; 31(4):370-7. PubMed ID: 12821070
[TBL] [Abstract][Full Text] [Related]
15. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.
Zhong Q; Peng HL; Zhao X; Zhang L; Hwang WT
Clin Cancer Res; 2015 Jan; 21(1):211-20. PubMed ID: 25348513
[TBL] [Abstract][Full Text] [Related]
16. Breast Cancer Risk Reduction Decisions of the BRCA-Positive Patient: An Observational Study at a Single Institution.
Johns D; Agarwal J; Anderson L; Ying J; Kohlmann W
J Womens Health (Larchmt); 2017 Jun; 26(6):702-706. PubMed ID: 27922795
[TBL] [Abstract][Full Text] [Related]
17. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer.
Kaas R; Verhoef S; Wesseling J; Rookus MA; Oldenburg HS; Peeters MJ; Rutgers EJ
Ann Surg; 2010 Mar; 251(3):488-92. PubMed ID: 20134318
[TBL] [Abstract][Full Text] [Related]
19. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
[TBL] [Abstract][Full Text] [Related]
20. A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?
Vos S; van Diest PJ; Moelans CB
Crit Rev Oncol Hematol; 2018 Jul; 127():29-41. PubMed ID: 29891109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
